Atezolizumab Combined With BDB001 AnD Immunogenic Radiotherapy in Patients With Advanced Solid Tumors
Status: RECRUITING
Study type: INTERVENTIONAL
Conditions: Solid Tumor, Adult|Pancreatic Cancer|Virus-associated Tumors|Non Small Cell Lung Cancer|Melanoma|Bladder Cancer|Triple Negative Breast Cancer
Interventions: DRUG: Association atezolizumab + BDB001 + RT|DRUG: Association atezolizumab + BDB001+ RT|DRUG: Association atezolizumab + BDB001+ RT|DRUG: Association atezolizumab + BDB001 + RT|DRUG: Association atezolizumab + BDB001 + RT|DRUG: Association atezolizumab + BDB001 + RT
Sponsor: Institut Bergonié
Collaborators: Roche Pharma AG|National Cancer Institute, France|Seven and Eight Biopharmaceuticals Inc